When does Victoza’s exclusivity end in the US?
The US “loss of exclusivity” timeline for Victoza (liraglutide) depends on which protection is ending: patent expiry, regulatory exclusivity (such as those tied to FDA application pathways), and possible additional protections for specific formulations or indications. The exact end date can’t be determined from the provided information, because it requires the relevant Orange Book entries and patent numbers for Victoza.
What counts as “loss of exclusivity” for Victoza—patents or FDA exclusivity?
In US drug markets, exclusivity typically ends when one or more of these expire:
- Patents listed in the FDA’s Orange Book for the product (composition, method-of-use, or formulation patents).
- FDA exclusivity tied to the original NDA approval pathway (the kind of exclusivity can differ by product and approval history).
- Any “additional” protections for line extensions or new indications, if they have separate listed protections.
Without the specific Victoza Orange Book patents/exclusivity codes in hand, the precise US date and what exactly is expiring can’t be stated.
Will generics or biosimilars launch immediately after exclusivity ends?
Even after exclusivity ends, an FDA-approved generic (or other follow-on product, where applicable) usually still needs:
- An approved application type (for small-molecule generics, the process differs from biologics; Victoza is a small-molecule drug delivered by pen device).
- Legal clearance regarding patents (sometimes via patent litigation and “skinny labeling”/carve-outs rather than immediate full launch).
So “loss of exclusivity” does not always equal “instant same-day competition.”
Where can I check the exact US “loss of exclusivity” date for Victoza?
To get the actual expiration date(s), check Victoza on the FDA Orange Book:
- Identify the listed patents and their expiration dates.
- Note any exclusivity periods associated with the NDA.
- Look for any approvals tied to additional indications that might extend protection.
If you share the relevant Orange Book patent list or the specific Victoza NDA number (and/or any patent numbers you’re looking at), I can help translate those dates into a clear “earliest possible entry” timeline.
Quick clarification: are you asking about Victoza, or another liraglutide brand?
In the US, “liraglutide” appears under multiple brands for different indications. If your question is about a different liraglutide product than Victoza (for example, for diabetes vs. weight management), the exclusivity landscape and listed protections can differ.
Sources
No sources were provided with the question, so I can’t cite specific Orange Book or FDA exclusivity records here.